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KEYWORDS	
	 Novel	 4(3H)‐quinazolinone	 derivatives	 with	 biologically	 active	 moieties	 were	 synthesized.
Reactions	 of	 2‐cyano‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)	 acetamide	 with	 carbon
disulfide,	isothiocyanates	followed	by	cycloalkylation	afforded	acrylamide,	1,3‐dithiazole,	1,3‐
dithiane,	 thiazole	 and	 pyrazole	 derivatives.	 The	 2‐pyridone	 derivatives	 were	 obtained	 via
reaction	 of	 cyanoacetamide	 with	 some	 acetylacetone	 or	 arylidenes.	 Cyclocondensation
reaction	 of	 cyanoacetamide	 with	 o‐hydroxy	 aldehydes	 furnished	 chromene	 derivatives.
Screening	 for	 some	 selected	 compounds	 was	 carried	 for	 their	 potential	 antitumor	 and
antifungal	 activities.	 2‐Cyano‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐2‐(4‐methyl‐3‐
phenyl‐thiazol‐2(3H)ylidene)‐acetamide	 with	 3‐side	 chain	 incorporated	 with	 substituted
thiazole	moiety	was	 found	 to	 be	 of	 high	 to	moderate	 activity	 towards	 cells.	 Also,	 the	 latter
product	showed	high	activity	against	Aspergillus	ochraceus	Wilhelm	with	inhibition	zone	(18
mm)	compared	with	(20	mm)	Nystatin	inhibition	zone.	
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1.	Introduction	
	
The	chemistry	of	4(3H)‐quinazolinone	system	has	received	
an	 increasing	 interest	 because	 of	 its	 biological	 significance.	
Many	 derivatives	 of	 this	 system	 showed	 antifungal	 [1],	
antibacterial	 [2],	 antitumor	 [3],	 antiinflammatory	 [4],	
anticonvulsant	 [5‐7],	 analgesic	 [8,9]	 and	 anti‐tuberculosis	
[10,11]	 activities.	 Cyanoacetamides	 are	 highly	 reactive	
compounds.	 The	 carbonyl	 and	 the	 cyano	 functions	 of	 these	
compounds	 are	 suitably	 situated	 to	 enable	 reactions	 with	
common	reagents	to	form	a	variety	of	heterocyclic	compounds.	
Also,	the	active	methylene	of	cyanoacetamide	can	take	part	in	a	
variety	 of	 condensation	 and	 substitution	 reactions.	Moreover,	
cyanoacetamides	 and	 their	 related	 heterocyclic	 derivatives	
have	 generated	 great	 attention	 due	 to	 their	 interesting	
biological,	 therapeutic	 value	 and	pharmaceutical	 activities	 e.g.	
as	 herbicidal	 [12]	 plant	 growth	 regulators	 [13]	 anti‐
inflammatory	 [14]	 anti‐tumor	 [15]	 and	 analgesic	 properties	
[16].	 Therefore,	 it	 was	 aimed	 in	 the	 present	 investigation	 to	
synthesize	 and	 characterize	 newer	 4(3H)‐quinazolinone	
derivatives	 for	 their	 expected	 antitumor	 and	 antimicrobial	
activities.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
All	 melting	 points	 are	 uncorrected.	 Microanalyses	 were	
carried	 out	 by	 the	 Microanalytical	 Laboratory,	 National	
Research	 Centre,	 Cairo,	 Egypt	 and	 the	Microanalytical	 Center,	
Cairo	 University.	 Infrared	 spectra	 (KBr	 disc)	 were	 recorded	
using	 a	 Jasco	 FT/IR‐300E	 spectrophotometer	 and	 FTIR	 5300	
spectrometer	 (ν,	 cm‐1).	 1H	 NMR	 spectra	 were	 recorded	 using	
Varian	 mercury	 300	 MHz	 or	 Varian	 Gemini	 200	 MHz	 with	
chemical	 shift	 in	 δ	 from	 Me4Si	 and	 Jeol	 270,	 500	 MHz.	 Mass	
spectra	 were	 recorded	 on	 GC/MS	 Finnigan	 SSQ	 7000	
spectrophotometer	&or	GC	Ms‐QP	1000	EX	mass	spectrometer	
at	70	eV.	
	
2.2.	Synthesis	
	
2.2.1.	2‐Cyano‐N‐(6‐iodo‐2‐methyl‐4(3H)‐quinazolinon‐3‐yl)	
acetamide	(2)	
	
3‐Amino‐quinazolinone,	 1,	 (0.01	 mol)	 was	 fused	 with	
excess	ethyl	cyanoacetate	at	~210	°C	in	an	oil‐bath	for	40	min.	
Excess	ethyl	cyanoacetate	was	evaporated	under	vacuum.	The	
solid	 product	 remained	 was	 triturated	 with	 ethanol	 (20	 mL)	
then	 filtered.	 The	 ethanolic	 filtrate	 was	 poured	 onto	 crushed	
ice.	 The	 solid	 product	 obtained	 was	 filtered	 and	 crystallized	
from	 toluene:ethyl	 acetate	 (1:1)	 to	 give	2	 as	 yellow	brownish	
crystals	 (Scheme	 1).	 Yield:	 80%.	 M.p.:	 215‐217	 °C.	 FT‐IR	 (ν,				
cm‐1):	3210	(NH),	2264	(C≡N),	1690	(C=O).	1H	NMR	(DMSO‐d6,	
δ,	 ppm):	 2.39	 (s,	 3H,	 CH3),	 4.10	 (m,	 2H,	 CH2),	 7.43	 (d,	 1H,	 J	 =	
8.40	Hz,	ArH	at	C8‐H),	8.15	(d,	1H,	J	=	8.40	Hz,	ArH	at	C7‐H),	8.37	
(s,	 1H,	ArH	at	C5‐H),	11.57	 (s,	 1H,	NH,	D2O‐exchangeable).	MS	
(m/z,	%):	368	(M+;	100).	Anal.	calcd	for	C12H9IN4O2:	C,	39.15;	H,	
2.46;	N,	15.22.	Found:	C,	39.10;	H,	2.50;	N,	15.20%.	
	
2.2.2.	General	procedure	for	the	syntheses	of	2‐(6‐iodo‐2‐
methyl‐3(4H)‐quinazolinonylamino)‐2‐oxo‐N'‐p‐arylaceto‐
hydrazonoylcyanide	(3a,b)		
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Scheme	1	
		
	
To	 aromatic	 amine	 (0.01	 mole)	 concentrated	 HCl	 (3	 mL)	
was	 added	 and	 cooled	 to	 ~0‐5	 oC	 in	 ice	 bath	 then	 cooled	
sodium	nitrite	solution	(1.0	g	in	10	mL	of	water)	was	added	to	
the	mixture	drop	wise	during	10	minutes.	The	reaction	mixture	
was	 then	 stirred	 for	 10	 minutes.	 A	 cold	 mixture	 of	 the	
cyanoacetamide	 derivative	2	 (0.01	mole)	 and	 sodium	 acetate	
(4.10	 g;	 0.05	mole)	 in	 ethanol	 (50	mL),	was	 then	 added	drop	
wise	 to	 the	 reaction	 mixture	 with	 stirring.	 The	 stirring	 was	
continued	for	30	minutes	and	the	reaction	mixture	was	left	for	
1	 hour	 at	 room	 temperature.	 The	 solid	 product	 obtained	was	
collected	by	filtration	and	crystallized	from	ethanol	to	give	the	
corresponding	hydrazono	derivatives,	3a,b,	 as	 yellow	 crystals	
(Scheme	1).	
2‐((6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)amino)‐2‐oxo‐
N'‐phenylacetohydrazonoyl	cyanide	(3a):	Yield:	80%.	M.p.:	234‐
236	 °C.	 FT‐IR	 (ν,	 cm‐1):	 3228	 (NH),	 2216	 (C≡N),	 1686	 (C=O).	
MS	(m/z,	%):	472	(M+;	8.4),	301	(100),	473	(3.2%),	301	(18.5),	
245	 (9.7),	 172	 (4.0),	 111	 (5.4).	Anal.	 calcd.	 for	C18H13IN6O2:	C,	
45.78;	H,	2.77;	N,	17.80.	Found:	C,	45.80;	H,	2.70;	N,	17.80%.	
2‐(6‐Iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐ylamino)‐2‐oxo‐
N'‐p‐tolylacetohydrazonoyl	cyanide	(3b):	Yield:	90%.	M.p.:	>300	
°C.	 FT‐IR	 (ν,	 cm‐1):	 3230	 (NH),	 2218	 (C≡N),	 1689	 (C=O).	 1H	
NMR	 (DMSO‐d6,	 δ,	 ppm):	 2.31	 (s,	 3H,	 CH3),	 2.40	 (s,	 3H,	 CH3),	
7.15	(d,	2H,	J	=	8.08	Hz,	AB	system),	7.50	(d,	1H,	J	=	8.57	Hz,	ArH	
at	C8‐H),	7.61	 (d,	2H,	 J	 =	8.08	Hz,	AB	system),	8.10	 (d,	1H,	 J	 =	
8.57	Hz,	ArH	at	C7‐H),	8.40	 (s,	1H,	ArH	at	C5‐H),	11.15	 (b,	1H,	
NH),	12.30	(b,	1H,	NH).	Anal.	calcd.	for	C19H15IN6O2:	C,	46.93;	H,	
3.11;	N,	17.28.	Found:	C,	46.90;	H,	3.10;	N,	17.30%.	
	
2.2.3.	General	procedure	for	synthesizing	2‐cyano‐2‐
(substituted)‐N‐(6‐iodo‐2‐methyl‐4(3H)quinazolinonyl)	
acetamides	(4,5	and	acrylamide	6)	
	
To	 a	 stirred	 suspension	 of	 finely	 powdered	 potassium	
hydroxide	(0.02	mole)	 in	dry	DMF	(10	mL)	cyanoacetamide	2	
(0.01	 mole)	 was	 added,	 the	 resulted	 mixture	 was	 cooled	 at							
10	oC	in	an	ice	bath,	then	carbon	disulfide	(0.01	mol)	was	added	
slowly	 over	 the	 course	 of	 10	min	 (Scheme	 1).	 After	 complete	
addition,	 stirring	 of	 the	 reaction	 mixture	 was	 continued	 for	
additional	 2	 h.	 Then	 dibromoethane,	 dibromopropane	 or	
dimethylsulfate	 (0.01	 mol)	 was	 added	 to	 the	 mixture	 while	
cooling	(~15	oC)	and	stirring	for	1	h.	then	poured	into	crushed	
ice,	 the	 resulting	 precipitate	 was	 filtrated	 off,	 dried	 and	
crystallized	from	the	proper	solvent	to	give:	
2‐Cyano‐2‐(1,3‐dithiolan‐2‐ylidene)‐N‐(6‐iodo‐2‐methyl‐4‐
oxoquinazolin‐3(4H)‐yl)acetamide	 (4):	 As	 yellow	 brownish	
crystals	 (benzene:ethanol;	 1:1).	 Yield:	 70%.	M.p.:	 243‐245	 °C.	
FT‐IR	 (ν,	 cm‐1):	 3266	 (NH),	 2971	 (CHaliph),	 2204	 (C≡N),	 1696,	
1666	(C=O).	1H	NMR	(CDCl3,	δ,	ppm):	2.44	(s,	3H,	CH3),	3.75	(s,	
4H,	2CH2),	7.50	(d,	1H,	J	=	8.10	Hz,	ArH	at	C8‐H),	8.20	(d,	1H,	J	=	
8.10	Hz,	ArH	at	 C7‐H),	8.42	 (s,	 1H,	ArH	at	 C5‐H),	 11.20	 (s,	 1H,	
NH,	 D2O‐exchangeable).	 MS	 (m/z,	 %):	 470	 (M+,	 22.2),	 170	
(100),	 471	 (2.8),	 172	 (17.2),	 75	 (16.5).	 Anal.	 calcd.	 for	
C15H11IN4O2S2:	 C,	 38.31;	H,	 2.36;	N,	 11.91.	 Found:	 C,	 38.30;	H,	
2.40;	N,	11.90%.	
2‐Cyano‐2‐(1,3‐dithian‐2‐ylidene)‐N‐(6‐iodo‐2‐methyl‐4‐
oxoquinazolin‐3(4H)‐yl)acetamide	 (5):	 As	 yellow	 brownish	
crystals	 (benzene:ethanol;	 1:1).	 Yield:	 75%.	M.p.:	 238‐240	 °C.	
FT‐IR	 (ν,	 cm‐1):	 3242	 (NH),	 2926	 (CHaliph),	 2200	 (C≡N),	 1703,	
1665	(C=O).	 1H	NMR	(CDCl3,	δ,	ppm):	2.20	(p,	2H,	 J	=	6.80	Hz,	
CH2),	2.50	(s,	3H,	CH3),	3.05	(t,	2H,	J	=	6.60	Hz,	CH2),	3.21	(t,	2H,	
J	=	6.60	Hz,	CH2),	7.42	(d,	1H,	J	=	8.50	Hz,	ArH	at	C8‐H),	8.14	(d,			
J	=	8.50	Hz,	1H,	ArH	at	C7‐H),	8.35	(s,	1H,	ArH	at	C5‐H),	11.06	(s,	
1H,	 NH,	 D2O‐exchangeable).	 Anal.	 calcd.	 for	 C16H13IN4O2S2:	 C,	
39.68;	H,	2.71;	N,	11.57.	Found:	C,	39.70;	H,	2.70;	N,	11.60%.	
2‐Cyano‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl‐3,3‐
bis(methylthio)acrylamide	 (6):	 As	 yellow	 brownish	 crystals	
(methanol).	Yield:	60%.	M.p.:	173‐175	°C.	FT‐IR	(ν,	cm‐1):	3212	
(NH),	2964,	2926	(CHaliph),	2200	(C≡N),	1688	(C=O).	MS	(m/z,	
%):	 472	 (M+,	 22.2),	 368	 (30.9),	 328	 (37.8),	 271	 (49.0),	 216	
(16.9),	 172	 (14.8),	 116	 (18.6),	 75	 (43.8).	 Anal.	 calcd.	 for	
C15H13IN4O2S2:	 C,	 38.14;	 H,	 2.77;	 N,	 11.86.	 Found:	 C38.10,	 H,	
2.80;	N,	11.90%.	
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Scheme	2
	
	
2.2.4.	2‐Cyano‐N‐(6‐iodo‐2‐methyl‐4(3H)‐quinazolinon‐3‐yl)‐
2‐(substituted)	acetamide	(8,9)	
	
To	 a	 stirred	 suspension	 of	 finely	 powdered	 potassium	
hydroxide	(0.01	mole)	 in	dry	DMF	(10	mL)	cyanoacetamide	2	
(0.01	mole)	was	 added,	 and	 then	 phenyl	 isothiocyanate	 (0.01	
mol)	 was	 added	 slowly	 (Scheme	 2).	 After	 complete	 addition,	
stirring	of	the	reaction	mixture	was	continued	for	additional	5	
h.	 Then	 chloroacetone	or	 ethyl	 chloroacetate	 (0.01	mole)	was	
added	to	the	mixture	and	the	reaction	mixture	was	stirred	for	2	
h.	 The	 reaction	 mixture	 was	 poured	 into	 crushed	 ice.	 The	
resulting	precipitate	was	filtrated	off,	dried	and	crystallized	to	
give:	
2‐Cyano‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl‐2‐(4‐
methyl‐3‐phenylthiazol‐2(3H)ylidene)acetamide	 (8):	 As	 yellow	
brownish	 crystals	 (acetic	 acid).	 Yield:	 75%.	M.p.:	 248‐250	 °C.	
FT‐IR	(ν,	cm‐1):	2973,	2926	(CHaliph),	2181	(C≡N),	1708	(C=O).	
1H	NMR	(DMSO‐d6,	δ,	ppm):	1.93	(s,	3H,	CH3	[thiazole]),	2.40	(s,	
3H,	CH3	[quinazoline]),	7.03	(s,	1H,	CH	[thiazole]),	7.52	(d,	1H,	J	
=	8.10	Hz,	ArH	at	C8‐H),	7.66	(m,	5H,	ArH),	8.17	(d,	1H,	J	=	8.10	
Hz,	ArH	at	C7‐H),	8.40	(s,	1H,	ArH	at	C5‐H),	9.93	(s,	1H,	NH,	D2O‐
exchangeable).	 MS	 (m/z,	 %):	 541(M+,	 1.8),	 214	 (100),	 327	
(48.2),	243	(45.7),	187	(8.2),	116	(11.0),	75	(17.5).	Anal.	calcd.	
for	C22H16IN5O2S:	C,48.81;	H,	2.98;	N,	12.94.	Found:	C,	48.80;	H,	
3.00;	N,	12.90%.	
2‐Cyano‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐2‐(4‐
oxo‐3‐phenylthiazolidin‐2‐ylidene)acetamide	 (9):	 As	 yellow	
brownish	crystals	(ethanol:dioxane;	2:1).	Yield:	70%.	M.p.:	193‐
195	°C.	FT‐IR	(ν,	cm‐1):	3188	(NH),	2924	(CHaliph),	2220	(C≡N),	
1688	(C=O).	1H	NMR	(DMSO‐d6,	δ,	ppm):	2.35	(s,	3H,	CH3),	4.00	
(s,	2H,	CH2[thiazole]),	7.30‐7.70	(m,	6H,	 [Ph‐H	 ,	ArH	at	C8‐H]),	
8.10	(d,	1H,	J	=	8.10	Hz,	ArH	at	C7‐H),	8.35	(s,	1H,	ArH	at	C5‐H),	
10.60	 (s,	 1H,	 NH,	 D2O‐exchangeable).	 Anal.	 calcd.	 for	
C21H14IN5O2S:	 C,	 46.42;	 H,	 2.60;	 N,	 12.89.	 Found:	 C,	 46.40;	 H,	
2.60;	N,	12.90%.	
	
2.2.5.	2‐Cyano‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐
yl)‐3‐(methylthio)‐3‐(phenylamino)acrylamide	(10)	
	
To	 suspension	 of	 potassium	hydroxide	 (0.01	mole)	 in	 dry	
DMF	(10	mL)	cyanoacetamide	2	(0.01	mole)	was	added	during	
stirring,	phenyl	isothiocyanate	(0.01	mol)	was	dropped	slowly	
to	the	reaction	mixture.	After	complete	addition,	stirring	of	the	
reaction	was	continued	for	5	h.	and	dimethyl	sulfate	(0.01	mol)	
was	 added.	 The	 reaction	 mixture	 was	 stirred	 for	 2	 h.	 then,	
poured	into	crushed	ice.	The	resulting	precipitate	was	filtrated	
off,	 dried	 and	 crystallized	 from	 benzene	 to	 give	10	 as	 yellow	
brownish	crystals	(Scheme	2).	Yield:	70%.	M.p.:	144‐145	°C.	FT‐
IR	 (ν,	 cm‐1):	 3244	 (NH),	 2194	 (C≡N),	 1658	 (C=O).	 1H	 NMR	
(DMSO‐d6,	δ,	ppm):	2.30	(s,	3H,	SCH3),	2.45	(s,	3H,	CH3),	7.35	(d,	
1H,	J	=	8.50	Hz,	ArH	at	C8‐H),	7.46	(m,	5H,	ArH),	8.20	(d,	1H,	J	=	
8.50	Hz,	ArH	at	 C7‐H),	8.41	 (s,	 1H,	ArH	at	 C5‐H),	 10.81	 (s,	 1H,	
NH,	 NHPh	 D2O‐exchangeable),	 11.78	 (s,	 1H,	 NH,	 CONH,	 D2O‐
exchangeable).	MS	(m/z,	%):	517	(M+),	127	 (100).	Anal.	 calcd.	
for	C20H16IN5O2S:	C,	46.43;	H,	3.12;	N,	13.54.	Found:	C,	46.40;	H,	
3.10;	N,	13.50%.	
	
2.2.6.	5‐amino‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐
yl)‐3‐(phenylamino)‐1H‐pyrazole‐4‐carboxamide	(11)	
	
A	mixture	 of	10	 (0.01	mol)	 and	hydrazine	hydrate	 (0.012	
mol)	in	ethanol	(30	mL)	was	heated	under	reflux	for	3	hrs	and	
allowed	 to	 cool.	 The	 solid	 product	 obtained	was	 filtrated	 and	
crystallized	 from	 acetic	 acid	 to	 give	 11	 as	 yellow	 crystals	
(Scheme	 2)	 Yield:	 65%.	 M.p.:	 300	 °C.	 FT‐IR	 (ν,	 cm‐1):	 3311,	
3199,	3159	(NH,	NH2),	1684	(C=O).	1H	NMR	(DMSO‐d6,	δ,	ppm):	
2.6	(s,	3H,	CH3),	5.8	(s,	2H,	NH2),	6.8‐8.4	(m,	8H,	ArH),	9.1	(s,	1H,	
NH),	 9.2	 (s,	 1H,	 NH),	 10.0	 (s,	 1H,	 NH).	 Anal.	 calcd.	 for	
C19H16IN7O2:	 C,	 45.52;	 H,	 3.22;	 N,	 19.56.	 Found:	 C,	 45.50;	 H,	
3.20;	N,	19.60%.	
	
2.2.7.	N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐5,7‐
dimethyl‐2)phenylamino)pyrazolo[1,5‐a]pyrimidine‐3‐
carboxamide	(12)	
	
A	mixture	 of	 compound	11	 (0.01	mol)	 and	 acetyl	 acetone	
(0.01	mol)	was	 heated	 under	 reflux	 in	 glacial	 acetic	 acid	 (20	
mL)	for	3	hrs	then	left	to	cool.	The	obtained	solid	product	was	
filtrated	 and	 crystallized	 from	 dioxane	 to	 give	 12	 as	 yellow	
brownish	crystals	(Scheme	2).	Yield:	65%.	M.p.:	>300	°C.	FT‐IR	
(ν,	cm‐1):	3253	(NH),	1705,	1656	(C=O).		
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Scheme	3
	
	
1H	NMR	(DMSO‐d6,	δ,	ppm):	2.50	(s,	6H,	2CH3),	2.63	(s,	3H,	CH3),	
6.90	 (t,	1H,	 J	=	7.55	Hz,	ArH	at	C4	of	phenyl	 ring),	7.11	 (s,	1H,	
CH‐pyrimidine),	 7.35	 (t,	 2H,	 J	 =	 7.55	Hz,	 ArH	 at	 C3,5	 of	 phenyl	
ring),	7.48	(d,	1H,	J	=	8.40	Hz,	ArH	at	C8‐H	of	quinazoline),	7.74	
(d,	2H,	 J	=	8.40	Hz,	ArH	at	C2,6	of	phenyl	ring),	8.15	(d,	1H,	 J	=	
8.40	 Hz,	 ArH	 at	 C7	 of	 quinazoline),	 8.38	 (s,	 1H,	 ArH	 at	 C5	 of	
quinazoline),	9.11	(b,	1H,	NH),	10.37	(b,	1H,	NH).	MS	(m/z,	%):	
565	(28.0),	265	(100),	566	(6.9),	238	(9.6),	174	(2.6),	134(7.8).	
Anal.	calcd.	for	C24H20IN7O2:	C,	50.99;	H,	3.57;	N,	17.34.	Found:	
C,	51.00;	H,	3.60;	N,	17.30%.	
	
2.2.8.	1‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐4,6‐
dimethyl‐2‐oxo‐1,2‐dihydro‐pyridine3‐carbonitrile	(13)	
	
A	mixture	 of	 cyanoacetamide	2	 (0.01	mol),	 acetyl	 acetone	
(0.012	mol)	and	pipridine	(few	drops)	was	placed	in	a	conical	
flask	and	 fused	 for	15	min.	 then	allowed	 to	 cool.	The	mixture	
was	triturated	with	ethanol	(20	mL)	and	the	solid	obtained	was	
collected	by	filtration	and	crystallized	from	dioxane	to	give	13	
as	pale	grey	crystals	(Scheme	3).	Yield:	85%.	M.p.:	>300	°C.	FT‐
IR	 (ν,	 cm‐1):	 2958	 (CHaliph),	 2218	 (C≡N),	 1680	 (C=O).	 1H	NMR	
(DMSO‐d6,	δ,	ppm):	2.25	(m,	6H,	2CH3),	2.48	(s,	3H,	CH3),	6.67	
(s,	1H,	Ar‐H),	7.54	(d,	1H,	J	=	8.40	Hz,	ArH	at	C8‐H),	8.25	(d,	1H,	J	
=	8.40	Hz,	ArH	at	C7‐H),	8.41	(s,	1H,	ArH	at	C5‐H).	MS	(m/z,	%):	
432	(M+),	416	(100),	433	(38.3),	434	(6.7),	290	(7.8),	257	(6.6),	
216	(19.8),	116(15.0),	75	(36.1).	Anal.	calcd.	for	C17H13IN4O2:	C,	
47.24;	H,	3.03;	N,	12.96.	Found:	C,	47.20;	H,	3.00;	N,	13.00%.	
	
2.2.9.	General	procedure	 for	 the	syntheses	of	6‐amino‐1‐(6‐
iodo‐2‐methyl‐4(3H)‐quinazolin‐3‐yl)‐4‐alkyl‐2‐oxo‐1,2‐
dihydro‐Pyridine‐3,5‐dicarbonitrile	(14a,b)	
	
To	 a	 mixture	 of	 2‐cyanoacetamide	 2	 (0.01	 mol),	
formaledehyde	 or	 acetaldehyde	 (0.01	mol)	 and	malononitrile	
(0.01	mol)	in	ethanol	(30	mL),	few	drop	of	pipridine	was	added.	
The	 reaction	mixture	was	 heated	 under	 reflux	 for	 3	 hrs.	 The	
solid	 product	 which	 formed	 while	 hot	 was	 collected	 by	
filtration	and	crystallized	from	dioxane	to	give	14a,b	as	yellow	
crystals	(Scheme	3).	
6‐Amino‐1‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐2‐
oxo‐1,2‐dihydropyridine‐3,5‐dicarbonitrile	 (14a):	M.p.:	 197‐195	
°C.	Yield:	70%.	FT‐IR	(ν,	cm‐1):	3353,	3204	(NH2),	2191	(C≡N),	
1694	(C=O).	MS	(m/z,	%):	444	(M+,	1.5),	286	(100).	Anal.	calcd.	
for	C16H9IN6O2:	C,	43.26;	H,	2.04;	N,	18.92.	Found:	C,	43.30;	H,	
2.00;	N,	18.90%.	
6‐Amino‐1‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐4‐
methyl‐2‐oxo‐1,2‐dihydropyridine‐3,5‐dicarbonitrile	(14b):	M.p.:	
277‐280°C.	Yield:	75%.	FT‐IR	(ν,	cm‐1):	3302,	3143	(NH2),	2218	
(C≡N),	 1696	 (C=O).	 1H	 NMR	 (DMSO‐d6,	 δ,	 ppm):	 2.20	 (s,	 3H,	
CH3‐quinazoline),	 2.50	 (s,	 3H,	 CH3‐	 pyridine),	 7.53	 (d,	 1H,	 J	 =	
8.40	Hz,	ArH	at	C8‐H),	8.15	(d,	1H,	J	=	8.70	Hz,	ArH	at	C7‐H),	8.40	
(s,	 1H,	 ArH	 at	 C5‐H),	 9.22	 (b,	 2H,	 NH2).	 Anal.	 calcd.	 for	
C17H11IN6O2:	 C,	 44.56;	 H,	 2.42;	 N,	 18.34.	 Found:	 C,	 44.60;	 H,	
2.40;	N,	18.40%.	
	
2.2.10.	General	procedure	for	the	syntheses	of	6‐amino‐1‐(6‐
iodo‐2‐methyl‐4(3H)‐quinazolinonyl)‐4‐(aryl)‐2‐oxo‐1,2‐
dihydro‐pyridine‐3,5‐dicarbonitriles	(15a,b)	
	
To	 equimolar	 amounts	 of	 2‐cyanoacetamide	 2	 and	 2‐(4‐
(chloro	or	methoxy)	benzylidene)	malononitrile,	 (0.01	mol)	 in	
ethanol	 (30	 mL)	 it	 was	 added	 few	 drop	 of	 pyridine.	 The	
reaction	 mixture	 was	 heated	 under	 reflux	 for	 3	 hrs	 then	
allowed	to	cool	and	poured	into	cold	diluted	HCl	solution.	The	
obtained	 product	 was	 collected	 by	 filtration	 and	 crystallized	
from	 the	 proper	 solvent	 to	 give	 pyridinone	 derivatives	15a,b	
(Scheme	3).	
6‐Amino‐1‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐4‐(4‐
methoxyphenyl)‐2‐oxo‐1,2‐dihydropyridine‐3,5‐dicarbonitrile	
(15a):	M.p.:	178‐180	°C.	Yield:	55%.	FT‐IR	(ν,	cm‐1):	3300,	3150	
(NH2),	2214	(C≡N),	1690	(C=O).	MS	(m/z,	%):	550	(M+,	94.7),	
508	(100),	551	(28.2),	552	(6.6).	Anal.	calcd.	for	C23H15IN6O3:	C,	
50.20;	H,	2.75;	N,	15.27.	Found:	C,	50.20;	H,	2.75;	N,	15.30%.	
6‐Amino‐4‐(4‐chlorophenyl)‐1‐(6‐iodo‐2‐methyl‐4‐oxo‐
quinazolin‐3(4H)‐yl)‐2‐oxo‐1,2‐dihydropyridine‐3,5‐dicarbo‐
nitrile	 (15b):	M.p.:	>300	 °C.	Yield:	65%.	FT‐IR	 (ν,	 cm‐1):	3285,	
3200	 (NH2),	 2219	 (C≡N),	 1695	 (C=O).	 1H	 NMR	 (DMSO‐d6,	 δ,	
ppm):	 2.40	 (s,	 3H,	 CH3),	 7.53	 (d,	 1H,	 J	 =	 8.10	 Hz,	 ArH	 at	 C8‐
quinazoline),	7.70	(m,	4H,	ArH),	8.20	(d,	1H,	J	=	8.10	Hz,	ArH	at	
C7‐	 quinazoline),	 8.43	 (s,	 1H,	 ArH	 at	 C5‐quinazoline),	 9.40	 (b,	
2H,	 NH2,	 D2O‐exchangeable).	 Anal.	 calcd.	 for	 C22H12ClIN6O2:	 C,	
47.63;	H,	2.18;	N,	15.15.	Found:	C,	47.60;	H,	2.20;	N,	15.10%.	
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2.2.11.	 6‐amino‐4‐(4‐(2,2‐dicyanovinyl)phenyl)‐1‐(6‐iodo‐2‐
methyl‐4‐oxoquinazolin‐3(4H)‐yl‐2‐oxo‐1,2dihydropyridine‐
3,5‐dicarbonitrile	(16)	
	
To	 a	 mixture	 of	 2‐cyanoacetamide	 2	 (0.01	 mol),	 ter‐
phthaledehyde	 (0.01	 mol)	 and	 malononitrile	 (0.02	 mol)	 in	
ethanol	(30	ml),	few	drop	of	pyridine	was	added.	The	reaction	
mixture	was	heated	 under	 reflux	 for	 3	 hrs.	 The	 solid	 product	
which	 formed	 while	 hot	 was	 collected	 by	 filtration	 and	
crystallized	from	dioxane	to	give	16	as	red	crystals	(Scheme	3).	
Yield:	85%.	M.p.:	258‐261	°C.	FT‐IR	(ν,	cm‐1):	3444,	3320,	3158	
(NH2),	 2212	 (C≡N),	 1644	 (C=O).	MS	 (m/z,	%):	 	 596	 (M+,	1.6),	
341	 (100),	 286	 (77.8),	 246	 (34.3),	 114	 (35.0),	 90	 (17.7)	Anal.	
calcd.	 for	 C26H13IN8O2:	 C52.37;	 H,	 2.20;	 N,	 18.79.	 Found:	 C,	
52.40;	H,	2.20;	N,	18.80%.	
	
2.2.12.	General	procedure	 for	 the	syntheses	of	chromene‐3‐
carboxamide	derivatives	(17‐19)	
	
A	 mixture	 cyanoacetamide	 2	 (0.01	 mol)	 and	
salicylaldehyde,	β‐naphthaldehyde	or	7‐hydroxy‐5‐methoxy‐2‐
methyl‐4‐oxo‐4H‐chromone‐6‐carboxaldehyde	 (0.01	 mol)	 in	
ethanol	 (30	 mL)	 containing	 ammonium	 acetate	 (0.3	 g)	 was	
heated	under	reflux	for	0.5	hrs	(Scheme	4).	The	obtained	solid	
product	which	formed	while	hot	was	collected	by	filtration	and	
crystallized	from	ethanol:dioxane	(2:1)	to	give:	
2‐Imino‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐2H‐
chromene‐3carboxamide	(17):	As	greenish	crystals.	Yield:	80%.	
M.p.:	 219‐221	 °C.	 FT‐IR	 (ν,	 cm‐1):	 3242	 (NH),	 1682	 (C=O).	 1H	
NMR	 (DMSO‐d6,	 δ,	 ppm):	 2.50	 (s,	 3H,	 CH3),	 6.90‐7.50	 (m,	 5H,	
[Ar‐H	+	NH]),	7.90	(d,	1H,	J	=	8.10	Hz,	ArH	at	C8‐H),	8.10	(d,	1H,	J	
=	8.10	Hz,	ArH	at	C7‐H),	8.40	(s,	1H,	ArH	at	C5‐H),	9.10	 (s,	1H,	
CH‐chromene),	10.60	(b,	1H,	NH,	D2O‐exchangeable).	MS	(m/z,	
%):	 472	 (M+),	 301	 (100),	474	 (2.3),	 396	 (2.4),	 368	 (5.0),	 245	
(19.6),	137	(20.5),	145	(12.6),	75	(11.7).	Anal.	calcd.	for	C19H13	
IN4O3:	 C48.32;	 H,	 2.77;	 N,	 11.86.	 Found:	 C,	 48.30;	 H,	 3.80;	 N,	
11.90%.	
2‐Imino‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐2H‐
benzo[h]chromene‐3carboxamide	 (18):	 As	 greenish	 crystals	
(ethanol:dioxane;	2:1).	Yield:	85%.	M.p.:	254‐256	 °C.	FT‐IR	 (ν,	
cm‐1):	3284	(NH),	1680	(C=O).	1H	NMR	(DMSO‐d6,	δ,	ppm):	2.50	
(s,	3H,	CH3),	6.90‐7.50	(m,	5H,	[Ar‐H	+	NH]),	7.90	(d,	1H,	J	=	8.10	
Hz,	ArH	at	C8‐H),	8.10	(d,	1H,	J	=	8.10	Hz,	ArH	at	C7‐H),	8.40	(s,	
1H,	ArH	at	C5‐H),	9.10	(s,	1H,	CH‐chromene),	10.60	(b,	1H,	NH,	
D2O‐exchangeable).	 MS	 (m/z,	 %):	 522	 (M+),	 301	 (100),	 523	
(M+1;	24.5),	494	(90.3),	477	(38.7),	222	(78.7),	193	(55.3),	139	
(37.6),	 111	 (20.6),	 75	 (46.6).	 Anal.	 calcd.	 for	 C23H15	 IN4O3:	 C,	
52.89;	H,	2.89;	N,	10.73.	Found:	C,	52.90;	H,	2.90;	N,	10.70%.	
2‐Imino‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐5‐
methoxy‐8‐methyl‐6‐oxo‐2,6‐dihydropyrano[3,2‐g]chromene‐
3carboxamide	 (19):	 As	 yellow	 crystals	 (dioxane).	 Yield:	 80%.	
M.p.:	254‐356	°C.	FT‐IR	(ν,	cm‐1):	3186	(NH),	1718,	1690	(C=O).	
MS	(m/z,	%):		584	(M+),	325	(100),	555	(31.0),	490	(13.6),	286	
(75.9),	 245	 (33.0),	 145	 (3.5),	 90	 (7.1).	 Anal.	 calcd.	 for	 C24H17	
IN4O6:	 C,	 49.33;	 H,	 2.93;	 N,	 9.60.	 Found:	 C,	 49.30;	 H,	 2.90;	 N,	
9.59%.	
	
2.3.	Antitumor	activity	against	Ehrlich	Ascites	Carcinoma	
cells	(EAC)	[17]	
	
In	vitro	short	term	cytotoxic	activity	of	the	compounds	was	
determined	 using	 Ehrlich	 Ascites	 Carcinoma	 (EAC)	 cells.	 The	
EAC	 cells	 that	were	 collected	 from	 the	 animal	 peritoneum	by	
aspiration	 were	 washed	 repeatedly	 with	 phosphate	 buffered	
saline	(PBS)	solution	to	free	 it	 from	blood.	The	viability	of	 the	
cells	 was	 checked	 in	 a	 haemocytometer.	 The	 cells	 (2.5	 x	 105	
tumor	cells/mL	PBS)	were	incubated	in	clean	sterile	tubes	with	
the	 test	 compounds	 (25,	 50,	 100	 µg/mL	 in	 dimethylsulfoxide	
(DMSO))	 for	 2h	 at	 37	 °C,	 keeping	 the	 final	 volume	 at	 0.9	mL.	
The	 volume	 of	 DMSO	 was	 pegged	 below	 0.1%	 of	 the	 total	
volume.	The	control	tube	had	10	µL	of	solvent.	The	final	volume	
was	 made	 up	 to	 0.9	 mL	 with	 PBS.	 To	 each	 tube100	 µL	 of	
Tryphan	blue	solution	was	added.	The	live	(without	stain)	and	
dead	 (with	 blue	 stain)	 cells	 were	 counted	 using	
haemocytometer	 and	 percent	 cell	 death	 was	 calculated.	
Exclusion	 test	 was	 carried	 out	 to	 calculate	 the	 percentage	 of	
nonviable	cells.	
	
% Cytotoxicity =
(Tdead- Cdead)
Ttotal
100X
	 	 (1)	
	
where	 Tdead	 is	 the	 number	 of	 dead	 cells	 in	 the	 treated	 group,	
Cdead	is	that	in	the	control	group	and	Ttotal	is	the	total	number	of	
dead	 and	 live	 cells	 in	 the	 test	 compound	 treated	 group.	 Cis‐
platin	was	used	as	the	standard.	
	
2.4.	Antifungal	activity	of	some	selected	synthesized	
compounds		
	
Two	 test	 organisms	 were	 used:	 Aspergillus	 ochraceus	
Wilhelm	 and	 Fusarium	 oxysporium	 (local	 strainidentified	 in	
Regional	 Center	 for	 fungi	 and	 its	 applications	 in	 Al‐Azher	
University).	Sterilized	discs	method	[18]	was	used.	Fresh	stock	
solutions	 (1	 mg/mL)	 of	 the	 synthesized	 compounds	 were	
prepared	 in	 redistilled	 dimethylsulfoxide	 according	 to	 the	
required	concentrations.	The	discs	were	impregnated	in	DMSO.	
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Each	disc	was	impregnated	with	0.1	mL	DMSO,	so	total	amount	
of	 compound	 contained	 in	 each	 disk	was	 100	 µg.	Media:	 Dox	
agar	was	prepared	and	sterilized	by	autoclaving	for	15	min	at	
121	°C,	 then	 the	medium	was	cooled	 to	50	 °C	 inoculated	with	
the	 previously	 prepared	 fungi	 suspension	 and	 poured	 in	
sterilize	petri	dishes.	The	medium	was	allowed	to	solidify	after	
a	 simple	 circular	 movement	 of	 the	 plates.	 Paper	 discs	
previously	 impregnated	with	 the	solution	of	 compounds	 to	be	
tested	 were	 placed	 on	 the	 plates.	 The	 plates	 were	 then	
incubated	 for	 72	 h	 at	 28	 °C.	 On	 each	 plate	 an	 appropriate	
reference	Nystatin	disc	was	applied.	To	ensure	that	the	solvent	
had	 no	 effect	 on	 fungi	 growth;	 a	 control	 test	 was	 performed	
with	 test	 medium	 supplemented	 with	 DMSO	 as	 the	 same	
procedures	 as	 used	 in	 the	 experiments.	 DMSO	 showed	 no	
inhibition	zones.	
Dilution	 method:	 To	 determine	 the	 MIC	 for	 highly	 active	
compounds	 dilution	 method	 [19]	 was	 used.	 The	 compounds	
were	 dissolved	 and	 then	 diluted	 using	 DMSO,	 two‐fold	 serial	
concentrations	of	the	compounds	were	employed	to	determine	
the	 MIC	 ranging	 from	 100	 to	 6	 µg/mL.	 The	 MIC‐value	 was	
determined	as	 the	 lowest	concentration	of	 the	compound	 that	
completely	inhibited	macroscopic	growth	of	microorganism.	
	
3.	Results	and	discussion		
	
The	 solvent‐free	 reaction	 of	 aryl	 amines	 with	 ethyl	
cyanoacetate	 is	 well	 known	 to	 constitute	 one	 of	 the	 most	
widely	 used	 synthetic	 methods.	 Thermal	 fusion	 of	 3‐amino‐
4(3H)‐quinazolinone	 [20],	 1,	 (above	 its	 melting	 point)	 with	
ethyl	 2‐cyanoacetate	 afforded 2‐cyano‐N‐(6‐iodo‐2‐methyl‐4‐
oxoquinazolin‐3(4H)‐yl)	 acetamide,	 2.	 In	 order	 to	 probe	 the	
reactivity	of	the	latter	cyanoacetamide	having	active	methylene	
moiety,	 its	 diazotization	 reaction	 was	 tried.	 Thus,	 upon	 its	
reaction	with	the	desired	diazonium	chloride	(obtained	in	situ	
by	diazotization	of	the	desired	aromatic	amine	using	a	mixture	
of	 sodium	nitrite	 and	HCl)	 in	 the	presence	of	 sodium	acetate;	
the	 corresponding	quinazolinone	hydrazono	derivatives,	3a,b,	
were	 obtained.	 Structures	 of	 the	 acetamide	 2	 and	 the	
hydrazono	 derivatives	 3a,b	 were	 inferred	 from	 correct	
analytical	analyses	and	spectral	determinations.	IR	spectrum	of	
product	2	showed	absorption	bands	at	3210	(NH),	2264	(C≡N)	
and	 1690	 cm‐1	 (C=O).	 Its	 1H	 NMR	 spectrum	 revealed	 the	
following	signals	at	δ:	2.39	(s,	3H,	CH3),	4.10	(m,	2H,	CH2),	7.43	
(d,	1H,	J	=	8.40	Hz,	ArH	at	C8‐H),	8.15	(d,	1H,	J	=	8.40	Hz,	ArH	at	
C7‐H),	 8.37	 (s,	 1H,	 ArH	 at	 C5‐H),	 11.57	 (s,	 1H,	 NH,	 D2O‐
exchangeable).	 Its	 mass	 spectrum	 exhibited	 a	 molecular	 ion	
peak	at	m/z	=	368	(base	peak).	1H	NMR	spectrum	of	3b	showed	
two	singlet	at	11.15	and	12.30	ppm	for	2	NH.	Mass	spectrum	of	
3a	 revealed	a	molecular	 ion	peak	at	m/z	=	472	(8.4%)	with	a	
base	peak	at	m/z	=	301.	
Upon	 stirring	 the	 cyanoacetamide	2	with	 carbon	disulfide	
in	 the	 presence	 of	 potassium	 hydroxide	 in	 N,N‐
dimethylformamide	 followed	 by	 cycloalkylation	 with	 1,2‐
dibromoethane	 afforded	 1,3‐dithiolane	 derivative,	 4.	 Also,	
stirring	 of	 2	 under	 the	 same	 reaction	 conditions	 with	 1,3‐
dibromopropane	 yielded	 2‐cyano‐2‐(1,3‐dithian‐2‐ylidene)‐N‐
(6‐iodo‐2‐methyl‐4‐oxo‐quinazolin‐3(4H)‐yl)	 acetamide,	 5,	 in	
good	yield.	Furthermore,	reaction	of	2	with	CS2	in	the	presence	
of	KOH,	followed	by	addition	of	dimethyl	sulfate	while	stirring	
and	 cooling,	 afforded	 2‐cyano‐N‐(6‐iodo‐2‐methyl‐4‐
oxoquinazolin‐3(4H)‐yl)‐3,3‐bis(methylthio)acrylamide,	 6	
(Scheme	 1).	 Elemental	 analyses	 and	 spectroscopic	 data	
accorded	 well	 the	 proposed	 structures	 of	 the	 acetamide	
derivatives,	 4,	 5	 and	 6.	 IR	 spectra	 of	 compounds	 4,	 5	 and	 6	
showed	characteristic	bands	for	NH,	CH‐aliphatic,	C≡N	and	C=O	
groups.	1H	NMR	spectrum	of	the	compound	4	revealed	signal	at	
δ	 3.75	 ppm	 (s,	 4H,	 2CH2‐dithiolane),	 mass	 spectrum	 of	
compound	 4	 showed	 a	 molecular	 ion	 peak	 at	 m/z	 =	 470	
(22.2%)	 with	 a	 base	 peak	 at	 m/z	 =	 170	 (100%).	 1H	 NMR	
spectrum	of	compound	5	showed	signals	for	dithiene	moiety	at	
δ	 2.20	ppm	 (p,	 2H,	 J	 =	 6.80	Hz,	 CH2),	 3.05	 (t,	 2H,	 J	 =	 6.60	Hz,	
CH2),	3.21	(t,	2H,	J	=	6.60	Hz,	CH2).	Mass	spectrum	of	6	showed	
a	molecular	 ion	peak	at	m/z	=	472	with	a	base	peak	at	m/z	=	
301	(100%).	
The	 reactivity	 of	 3(4H)‐quinazolinone	 cyanoacetamide,	 2,	
toward	isothiocyanates	was	investigated.	Thus,	when	2	was	left	
to	react	with	phenyl	isothiocyanate	in	the	presence	of	solution	
of	 potassium	 hydroxide	 at	 room	 temperature	 and	 then	
chloroacetone	was	added;	 the	corresponding	4‐methylthiazole	
derivative,	8,	was	obtained,	as	a	clean	cut	product,	in	good	yield	
without	 affording	 the	 expected	 thiophene	 structure	 of	 type	7.	
Probably	 the	 reaction	 mechanism	 is	 assumed	 to	 proceed	 via	
initial	 alkylation	 followed	by	 in	 situ	 heterocyclization	 through	
nucleophilic	 addition	 of	 secondary	 amino	 group	 to	 carbonyl	
group	of	chloroacetone	to	yield	 the	cyclic	product:	2‐cyano‐N‐
(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐2‐(4‐methyl‐3‐
phenylthiazol‐2(3H)‐ylidene)acetamide,	8.	 Similarly,	 the	 novel	
2‐cyano‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐2‐(4‐
oxo‐3‐phenylthiazolidin‐2‐ylidene)‐acetamide,	 9,	 was	 synt‐
hesized	 from	 reaction	 of	2	 with	 phenyl	 isothiocyanate	 in	 the	
presence	 of	 potassium	 hydroxide	 followed	 by	 in	 situ	
heterocyclization	 of	 the	 resulting	 adduct	 with	 ethyl	
chloroacetate.	 Also,	 when	 2‐cyano‐N‐(6‐iodo‐2‐methyl‐4‐
oxoquinazolin‐3(4H)‐yl)	acetamide,	2,	was	left	to	react	with	the	
same	 isothiocyanate	 in	 the	 presence	 of	 (CH3)2SO4	 in	 alkaline	
medium,	 the	 corresponding	 2‐cyano‐N‐(6‐iodo‐2‐methyl‐4‐
oxoquinazolin‐3(4H)‐yl)‐3‐(methyl‐thio)‐3‐(phenylamino)‐
acrylamide,	 10,	 was	 afforded.	 Cyclocondensation	 of	 the	 acryl	
amide,	 10,	 with	 hydrazine	 hydrate	 in	 refluxing	 ethanol	
furnished	5‐amino‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐
yl)‐3‐(phenylamino)‐1H‐pyrazole‐4‐carboxamide,	11.		
Presumably,	formation	of	the	aminopyrazole	11	is	assumed	
to	proceed	via	Michael	addition	of	 the	hydrazino	amino	group	
to	the	ethylenic	bond	side	chain	in	10	with	elimination	of	SCH3	
group	 followed	 by	 intramolecular	 cyclization	 at	 the	 cyano	
group.	 When	 product	 11	 was	 heated	 under	 reflux	 with	
acetylacetone	 in	 glacial	 acetic	 acid;	 the	 pyrazolo[1,5‐
a]pyrimidine	derivative,	12,	was	afforded	(Scheme	2).	1H	NMR	
spectrum	 (DMSO‐d6)	 of	8	 displayed	 the	 following	 signals	 at	 δ	
1.93	(s,	3H,	CH3	[thiazole]),	2.40	(s,	3H,	CH3	[quinazoline]),	7.03	
(s,	1H,	CH	[thiazole]),	9.93	ppm	(s,	1H,	NH,	D2O‐exchangeable).	
Its	mass	spectrum	revealed	a	molecular	ion	peak	at	m/z	=	541	
with	a	base	peak	at	m/z	=	214	(100%).	1H	NMR	spectrum	of	9	
revealed	signals	at	δ	=	4.00	(s,	2H,	CH2[thiazole]),	10.60	ppm	(s,	
1H,	NH	(D2O‐exchangeable)).	1H	NMR	spectrum	of	10	displayed	
the	following	signals	at	δ	=	2.30	(s,	3H,	SCH3),	2.45	(s,	3H,	CH3),	
10.81	ppm	(s,	1H,	NH,	NHPh	(D2O‐	exchangeable)),	11.78	(s,	1H,	
NH,	CONH‐(D2O‐exchangeable)).	Mass	spectrum	of	10	revealed	
a	molecular	 ion	peak	at	m/z	=	517	with	a	base	peak	at	m/z	=	
127.	
IR	spectrum	of	11	showed	bands	at	3311,	3199,	3159	(NH,	
NH2)	 and	 1684	 (C=O)	 cm‐1.	 Its	 1H	 NMR	 spectrum	 showed	
signals	at	δ	=	2.6	(s,	3H,	CH3),	5.8	(s,	2H,	NH2),	6.8‐8.4	(m,	8H,	
ArH),	9.1	(s,	1H,	NH),	9.2	(s,	1H,	NH),	10.0	ppm	(s,	1H,	NH).	1H	
NMR	spectrum	(DMSO‐d6)	of	12	displayed	signals	a	δ	=	2.50	(s,	
6H,	2CH3),	2.63	(s,	3H,	CH3),	6.90	(t,	1H,	J	=	7.55	Hz,	ArH	at	C4	of	
phenyl	 ring),	7.11	 (s,	1H,	CH‐pyrimidine),	7.35	 (t,	2H,	 J	 =	7.55	
Hz,	ArH	at	C3,5	of	phenyl	ring),	7.48	(d,	1H,	J	=	8.40	Hz,	ArH	at	C8	
of	quinazoline),	7.74	(d,	2H,	J	=	8.40	Hz,	ArH	at	C2,6	of	phenyl	
ring),	8.15	(d,	1H,		J	=	8.40	Hz,	ArH	at	C7	of	quinazoline),	8.38	(s,	
1H,	 ArH	 at	 C5	 of	 quinazoline),	 9.11	 (b,	 1H,	NH),	 10.37	 (b,	 1H,	
NH).	Its	Mass	spectrum	revealed	a	molecular	ion	peak	at	m/z	=	
566	with	a	base	peak	at	m/z	=	265.	
It	 is	 well	 known	 that	 many	 2‐pyridone	 derivatives	
exhibited	diverse	biological	activities	e.g.	as	cardiotonic	agents,	
potential	HIV‐1	specific	reverse	transcriptase	inhibitors	[21,22]	
and	elastase	 inhibitors	 [23].	The	present	study	was	continued	
to	report	the	reactivity	of	cyanoacetamide	derivative	2	towards	
certain	 nucleophilic	 reagents.	 Thus,	 when	 2	 was	 thermally	
fused	with	acetylacetone	in	the	presence	of	a	catalytic	amount	
of	piperidine	cyclocondensation	reaction	occurred	and	the	4,6‐
dimethyl‐2‐pyridine	 derivative	 13	 was	 smoothly	 afforded.	 It	
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can	 be	 postulated	 that	 the	 reaction	 initially	 proceeds	 via	 a	
nucleophilic	attack	to	form	Michael	adduct	(13a)	which	in	turn	
cyclized	 to	 the	 adduct	 (13b)	 then	 lost	 two	 water	 molecules	
affording	 1‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐4,6‐
dimethyl‐2‐oxo‐1,2‐dihydro‐pyridine‐3‐carbonitrile,	 13,	
(Scheme	3).	
IR	 spectrum	 of	 the	 pyridine,	13,	 exhibited	 bands	 at	 2958	
(CH‐aliphatic),	 2218	 (C≡N)	 and	 1680	 (C=O)	 cm‐1.	 Its	 1H	NMR	
spectrum	 displayed	 the	 following	 signals	 2.25	 (m,	 6H,	 2CH3),	
2.48	(s,	3H,	CH3),	6.67	(s,	1H,	Ar‐H),	7.54	(d,	1H,	J	=	8.40	Hz,	ArH	
at	C8‐H),	8.25	(d,	1H,	J	=	8.40	Hz,	ArH	at	C7‐H),	8.41	(s,	1H,	ArH	
at	C5‐H).	Mass	spectrum	revealed	a	molecular	ion	peak	at	m/z	=	
432	 corresponding	 to	 a	 molecular	 formula	 C17H13IN4O2	
together	with	a	base	peak	at	m/z	=	416	(100%).	
One‐pot	reactions	of	the	cyanoacetamide	derivative,	2,	with	
malononitrile	 and	 (formaldehyde	 or	 acetaldehyde)	 (1:1:1	
molar	ratio)	at	reflux	temperature	in	ethanol	in	the	presence	of	
piperidine	 afforded	 the	 2‐pyridinone	 derivatives,	 14a,b,	
respectively.	 On	 the	 other	 hand,	 the	 2‐pyridinone	 derivatives	
15a,b	and	16	were	obtained	via	reaction	of	cyanoacetamide,	2,	
with	 2‐(4‐chlorobenzylidene)	 malononitrile	 or	 2‐(4‐methoxy‐
benzylidene)malononitrile	 (1:1:1	 molar	 ratio)	 or	 with	 ter‐
phthaldehyde	 and	 malononitrile	 (1:1:2	 molar	 ratio)	 upon	
heating	 under	 reflux	 in	 the	 presence	 of	 a	 catalyst.	 Structural	
assignment	 of	 the	 pyridinones	 14a,b,	 15a,b	 and	 16	 was	
confirmed	 on	 the	 basis	 of	 correct	 elemental	 analyses	 and	
spectral	 determination.	 IR	 spectrum	 of	14b	 showed	 bands	 at	
3353,	 3204	 cm‐1	 for	 NH2	 group.	 1H	 NMR	 spectrum	 of	 14b	
revealed	 signal	 at	 2.20	 (s,	 3H,	 CH3‐quniazoline),	 2.50	 (s,	 3H,	
CH3‐pyridine),	7.53	(d,	1H,	J	=	8.40	Hz,	ArH	at	C8‐H),	8.15	(d,	1H,	
J	=	8.70	Hz,	ArH	at	C7‐H),	8.40	(s,	1H,	ArH	at	C5‐H),	9.22	(b,	2H,	
NH2)	ppm.	Mass	spectrum	of	15a	showed	a	molecular	ion	peak	
at	m/z	=	550	(94.70%)	with	base	beaks	at	m/z	=	508.	Also,	one	
pot	 reaction	 of	 cyanoacetamide	 derivative	 2	 with	 ter‐
phthaldehyde	 and	 malononitrile	 (1:1:2	 molar	 ratio)	 at	 reflux	
temperature	 in	 ethanol	 in	 the	 presence	 of	 piperidine	 (few	
drops)	 afforded	 the	 2‐pyridinone	 derivative,	 16,	 (Scheme	 3).	
Mass	 spectrum	 of	16	 showed	 a	molecular	 ion	 peak	 at	m/z	 =	
596	(1.6%)	corresponding	to	a	molecular	formula,	C26H13IN8O2,	
with	a	base	peak	at	m/z	=	341	(100	%).	
Chromene	 derivatives	 are	 widely	 used	 for	 production	 of	
highly	 effective	 fluorescent	 dyes	 for	 synthetic	 fibers	 and	
daylight	 fluorescent	 pigments	 [24,25].	 Some	 derivatives	 play	
also	a	vital	role	in	electro	photographic	and	electroluminescent	
devices	[26]	Moreover,	many	other	derivatives	are	well	known	
for	 their	 considerable	 biological	 and	medicinal	 activities	 [27].	
Cyclocondensation	 reaction	 of	 2	 with	 salicylaldehyde	 or	 2‐
hydroxynaphthaldehyde	 or	 7‐hydroxy‐5‐methoxy‐2‐methyl‐4‐
oxo‐4H‐chromone‐6‐carboxaldehyde	 in	 ethanol	 containing	
ammonium	 acetate	 furnished	 smoothly	 2‐imino‐N‐(6‐iodo‐2‐
methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐2H‐chromene‐3‐carbox‐
amide,	 17,	 2‐imino‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐
3(4H)‐yl)‐2H‐benzo[H]chromene‐3‐carbox	 amide,	 18,	 and	 2‐
imino‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐5‐met‐
hoxy‐8‐methyl‐6‐oxo‐2,6‐dihydropyrano[3,2‐g]‐	 chromene‐3‐
carboxamide,	19,	respectively	(Scheme	4).	
1H	 NMR	 spectrum	 of	 17	 showed	 characteristic	 signals	 at	
9.11	for	CH‐chromene	and	at	10.60	ppm	for	NH.	Mass	spectrum	
of	 17	 exhibited	 a	 molecular	 ion	 peak	 at	 m/z	 =	 472.	 Mass	
spectrum	 of	 compound	18	 exhibited	 a	molecular	 ion	 peak	 at	
m/z	 =	 522.	 IR	 spectrum	 of	 the	 pyrano‐chromene	 19	 showed	
absorption	 bands	 at	 3186	 and	 1718	 cm‐1	 for	 NH	 and	 C=O,	
respectively.	Its	mass	spectrum	revealed	molecular	ion	peak	at	
m/z	=	584.	
Some	 selected	 examples	 from	 the	 synthesized	 products	
were	tested	using	the	short	 term	in	vitro	cytotoxicity	 towards	
Ehrlich	ascites	carcinoma	cells	(EAC)	as	a	preliminary	screening	
technique	of	tryphan	blue	exclusion	method	(cell	viability	test)	
for	 their	 potential	 cytotoxicity	 activity	 using	 100,	 50	 and	 25	
µg/mL	 concentrations.	 Structure	 activity	 relationship	 (SAR)	
indicated	that	the	thio	compounds	4,	8	and	10	showed	that	the	
quinazolinone	 derivative	 4	 with	 C‐3	 side	 chain	 having	
dithiolane	 moiety	 was	 found	 of	 no	 activity	 at	 the	 used	
concentrations.	Product	8	with	3‐side	chain	 incorporated	with	
substituted	 thiazole	 moiety	 was	 found	 to	 be	 of	 high	 to	
moderate	 activity	 towards	 cells	 at	 100	 (50%)	 and	 50	 (20%)	
µg/mL,	 respectively.	 Presumably	 the	 activity	 showed	 by	
compound	8	was	due	to	the	presence	of	the	thiazole	ring	in	its	
structure.	On	the	other	hand,	product	10	with	methyl	mercapto	
group	attached	in	its	3‐position	was	of	low	activity	(10%)	only	
at	100	µg/mL	(Table	1).	
	
Table	1.	Antitumor	activity	of	the	screened	compounds.	
Compound	No.	
%	Cell	death	at	different	concentrations	
(µg/mL)	after	2	h	
100 50	 25
4 0 0	 0 
8 50 20	 0
10 10 0	 0
	
The	 preliminary	 in	 vitro	 antifungal	 activity	 screening	 for	
some	 selected	 examples	 of	 the	 synthesized	 compounds	 was	
carried	 out	 using	 paper	 disc	 method	 against	 Aspergillus	
ochraceus	Wilhelm	and	Fusarium	oxysporium	fungi.	Fresh	stock	
solutions	 (1	mg/mL)	of	 the	 tested	 compounds	were	prepared	
in	 redistilled	DMSO	 according	 to	 the	 required	 concentrations.	
Serial	 concentrations	 of	 the	 compounds	 were	 employed	 to	
determine	 the	 (MIC)	 ranging	 from	 100	 to	 6.25	 μg/mL.	 The	
incubation	 for	 impregnated	 discs	 was	 72	 h	 at	 28	 °C.	 The	
antifungal	Nystatin	and	the	DMSO	solvent	were	used	as	positive	
and	 negative	 controls,	 respectively.	 The	 results	 showed	
compound	8	incorporating	a	thiazole	moiety	and	the	chromene	
product	 19	 were	 only	 of	 high	 activity	 against	 Fusarium	
oxysporium	 with	 inhibition	 zones	 (18	 mm)	 and	 (16	 mm),	
respectively,	compared	with	(20	mm)	Nystatin	inhibition	zone.	
MIC	of	compounds	8,	19	was	12.5	μg/mL.	All	 the	other	 tested	
compounds	showed	no	activity	 towards	 the	used	 fungi	 (Table	
2).	
	
Table	2.	Antimicrobial	activities	data	of	some	synthesized	compounds.	
Compound	No.	
Fungi	
Asperg.	Sp.	 Fuzarium	sp.	
8 0 18	(12.5)
13 0 0	
15a 0 0	
19 0 16	(12.5)	
Nystatin	 12	 20	
	
4.	Conclusion	
	
Novel	4(3H)‐quinazolinone	 derivatives	 bearing	 thiazole,	
pyrazole,	 1,3‐dithiazole,	 pyridine,	 pyrazolopyrimidine,	
chromene	and	pyranochromene	moieties	were	synthesized	and	
characterized.	 Screening	 of	 some	 selected	 compounds	 was	
carried	for	their	potential	antitumor	and	antifungal	activity.	2‐
Cyano‐N‐(6‐iodo‐2‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)‐2‐(4‐
methyl‐3‐phenyl‐thiazol‐2(3H)ylidene)‐acetamide,	 8,	 with	 3‐
side	 chain	 incorporated	with	 substituted	 thiazole	moiety	was	
found	 to	be	 of	 high	 to	moderate	 activity	 towards	EAC	 cells	 at	
100	 (50%)	 and	50	 (20%)	µg/mL	 respectively.	Also,	 the	 latter	
product	 showed	 high	 activity	 against	 Aspergillus	 ochraceus	
Wilhelm	with	inhibition	zone	(18	mm)	compared	with	(20	mm)	
Nystatin	inhibition	zone.	
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